去甲万古霉素群体药代动力学与药效学优化研究

目的研究去甲万古霉素群体药代动力学指标差异,对患者进行药效学优化。方法选取2015年1月至2015年12月268例感染患者,将其按照年龄分为中青年组和老年组,每组各134例,采用群体药代动力学和药效学优化公式进行计算,分析患者上述指标差异。结果青年组与老年组的群体药代动力学各项指标差异明显具有统计学意义(P0.05)。结论感染患者通过去甲万古霉素药物治疗疗效确切,对革兰阳性菌的杀灭作用明显,采用群体药代动力学和药效学研究后发现,AUC24/MIC能够作为去甲万古霉素的应用指标,并以此指导临床用药效果显著,值得临床应用推广。

Study on the Pharmacokinetics and Pharmacodynamics of Vancomycin in Population

Objective To study the difference of the pharmacokinetic parameters between the groups and to optimize the pharmacodynamics of the patients.Methods In our hospital from January 2015 to December 2015 were 268 cases, according to the divided into young group and the old age group, 134 cases in each group, the pharmacokinetics and pharmacodynamics of group medicine formula optimization, analysis of differences between patients with the above indexes.Results There were significant differences between the young group and the old group in the pharmacokinetic parameters of each group (P<0.05).Conclusion The curative effect of vancomycin to patients infected by drug treatment is effective, obvious killing effect on Gram positive bacteria, the pharmacokinetic and pharmacodynamic study of population pharmacokinetics showed that AUC24/MIC can use as indicators of norvancomycin, and to guide the clinical medication effect is significant, worthy of clinical application.